On Monday, Pain Therapeutics, Inc. (NASDAQ:PTIE)’s shares declined -5.45% to $2.08.
Pain Therapeutics, Inc. (PTIE) declared top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its lead drug candidate that is specifically designed to discourage certain common methods of drug tampering and misuse.
This study demonstrated with statistical significance (p<0.0001) that both intact and chewed REMOXY were less “liked” than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The company’s lead drug candidate is REMOXY, an extended-release oral formulation of oxycodone for the administration of moderate-to-severe pain when a continuous and around-the-clock opioid analgesic is needed.
Endo International plc - Ordinary Shares (NASDAQ:ENDP)’s shares dropped -5.37% to $80.77.
Endo International plc - Ordinary Shares (ENDP) declared that they have reached a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, counting assumption of Par debt. The combination will create a leading specialty pharmaceutical company with a generics business that is one of the industry’s fastest growing and among the top five as measured by U.S. sales. It is also predictable to assist drive long-term double-digit revenue growth for Endo. The transaction has been unanimously approved by the Boards of Directors of Endo and Par, and is supported by the administration teams of both companies. There are no further shareholder approvals required.
The purchase price will comprise of about 18 million shares ($1.55 billion of value based on the 10-day volume weighted average share price of Endo ending on May 15, 2015) of Endo equity and $6.50 billion cash consideration to Par shareholders. Endo has secured fully committed financing from Deutsche Bank and Barclays to fund the cash consideration. Endo anticipates to implement a permanent capital structure to finance the transaction preceding to the close that would comprise a combination of cash, debt and an equity offering.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals.
At the end of Monday’s trade, China Mobile Ltd. (ADR) (NYSE:CHL)‘s shares dipped -4.11% to $67.63.
China Mobile Ltd. (ADR) (CHL) declared that it has filed its Annual Report on Form 20-F for the year ended December 31, 2014 (the “2014 Form 20-F”) with the U.S. Securities and Exchange Commission.
The 2014 Form 20-F is accessible on the Investor Relations section of the Company’s website at http://www.chinamobileltd.com and on the SEC’s website at http://www.sec.gov. Shareholders may also request a hard copy of the Company’s complete audited financial statements, free of charge, by contacting the Company at Investor Relations Department, China Mobile Limited, 60/F, The Center, 99 Queen’s Road Central, Hong Kong.
China Mobile Limited, an investment holding company, provides mobile telecommunications and related services in Mainland China and Hong Kong. It offers voice services comprising local calls, domestic and international long distance calls, intra-provincial roaming, inter-provincial roaming, and international roaming, in addition to voice value-added services, counting caller identity display, caller restrictions, call waiting, call forwarding, call holding, voice mails, conference calls, and others.
Vantage Drilling Company (NYSEMKT:VTG), ended its Monday’s trading session with -4.76% loss, and closed at $0.400.
Vantage Drilling Company (VTG) reports net income for the three months ended March 31, 2015 of $21.4 million or $.06 per diluted share as contrast to earnings of $24.8 million or $.07 per diluted share for the three months ended March 31, 2014.
The three months ended March 31, 2015 comprises an about $20.6 million gain on the early retirement of debt. This gain represents the discount to the face value of debt that we purchased in the open market, net of writing off deferred financing costs. While this gain is not taxable, it is still comprised of in our calculation of annual effective tax rate which required us to record an additional adjustment to our tax provision for the three months ended March 31, 2015 of about $5.0 million.
Vantage Drilling Company, through its auxiliaries, provides offshore contract drilling services in the United States and internationally. It offers drilling units, related equipment, and work crews under contract to drill oil and natural gas wells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
